Goldman Sachs Group Inc. reduced its position in shares of Masimo Co. (NASDAQ:MASI) by 20.2% in the fourth quarter, HoldingsChannel.com reports. The firm owned 361,213 shares of the medical equipment provider’s stock after selling 91,625 shares during the period. Goldman Sachs Group Inc.’s holdings in Masimo were worth $30,632,000 at the end of the most recent quarter.
Other institutional investors have also recently bought and sold shares of the company. USA Mutuals Advisors Inc. purchased a new stake in shares of Masimo during the fourth quarter worth about $110,000. SeaCrest Wealth Management LLC purchased a new stake in Masimo in the fourth quarter worth about $116,000. Advisors Preferred LLC purchased a new stake in Masimo in the fourth quarter worth about $158,000. DekaBank Deutsche Girozentrale lifted its holdings in Masimo by 78.3% in the third quarter. DekaBank Deutsche Girozentrale now owns 2,106 shares of the medical equipment provider’s stock worth $182,000 after buying an additional 925 shares during the period. Finally, MANA Advisors LLC purchased a new stake in Masimo in the fourth quarter worth about $227,000. Institutional investors own 82.74% of the company’s stock.
In other news, EVP Yongsam Lee sold 10,000 shares of Masimo stock in a transaction that occurred on Thursday, February 1st. The shares were sold at an average price of $92.95, for a total transaction of $929,500.00. Following the completion of the transaction, the executive vice president now directly owns 79,000 shares in the company, valued at $7,343,050. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Sanford Fitch sold 2,000 shares of Masimo stock in a transaction that occurred on Thursday, February 1st. The shares were sold at an average price of $93.07, for a total transaction of $186,140.00. Following the transaction, the director now owns 68,249 shares of the company’s stock, valued at $6,351,934.43. The disclosure for this sale can be found here. Insiders have sold 24,100 shares of company stock valued at $2,186,340 over the last quarter. Company insiders own 16.60% of the company’s stock.
Several analysts have commented on MASI shares. Zacks Investment Research lowered shares of Masimo from a “buy” rating to a “hold” rating in a report on Wednesday, January 3rd. BidaskClub lowered shares of Masimo from a “hold” rating to a “sell” rating in a report on Thursday, December 7th. Barclays started coverage on shares of Masimo in a report on Friday, March 9th. They issued an “overweight” rating and a $97.00 price objective for the company. Finally, Piper Jaffray Companies restated a “hold” rating and issued a $91.00 price objective on shares of Masimo in a report on Thursday, March 1st. Two analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. The company presently has an average rating of “Buy” and an average target price of $101.00.
Shares of Masimo Co. (MASI) opened at $85.67 on Friday. Masimo Co. has a 1-year low of $80.69 and a 1-year high of $104.71. The company has a market cap of $4,505.27, a PE ratio of 30.94, a price-to-earnings-growth ratio of 2.29 and a beta of 0.92.
Masimo (NASDAQ:MASI) last released its earnings results on Tuesday, February 27th. The medical equipment provider reported $0.72 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.61 by $0.11. Masimo had a net margin of 16.49% and a return on equity of 22.75%. The firm had revenue of $225.20 million during the quarter, compared to analyst estimates of $201.54 million. During the same period last year, the business earned $0.46 earnings per share. The business’s revenue was up 22.9% on a year-over-year basis. analysts forecast that Masimo Co. will post 2.81 EPS for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: “Goldman Sachs Group Inc. Has $30.63 Million Stake in Masimo Co. (MASI)” was originally reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this article on another website, it was copied illegally and republished in violation of U.S. & international trademark & copyright laws. The legal version of this article can be accessed at https://www.dispatchtribunal.com/2018/03/23/goldman-sachs-group-inc-has-30-63-million-stake-in-masimo-co-masi.html.
Masimo Company Profile
Masimo Corporation is a medical technology company that develops, manufactures and markets a range of non-invasive patient monitoring technologies. The Company’s business is Measure-through Motion and Low Perfusion pulse oximetry monitoring, known as Masimo Signal Extraction Technology (SET) pulse oximetry.
Want to see what other hedge funds are holding MASI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Masimo Co. (NASDAQ:MASI).
Receive News & Ratings for Masimo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Masimo and related companies with MarketBeat.com's FREE daily email newsletter.